Clinical applications of quinolones

被引:127
作者
Hooper, DC [1 ]
机构
[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA 02114 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION | 1998年 / 1400卷 / 1-3期
关键词
quinolone; infection; resistance; pharmacology; DNA gyrase; topoisomerase IV;
D O I
10.1016/S0167-4781(98)00127-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The quinolone antimicrobials are the class of inhibitors of bacterial topoisomerases that has been developed most fully for clinical use in human medicine. Initial members of the class had their greatest potency against Gram-negative bacteria, but newly developed members have exhibited increased potency against Gram-positive bacteria and soon agents will be available with additional activity against anaerobic bacteria, providing a broad spectrum of potency. After nalidixic acid, the earliest member of the class which was used for treatment of urinary tract infections, the later fluoroquinolone congeners have had sufficient potency, absorption, and distribution into tissue for additional uses in treatment of sexually transmitted diseases, infections of the gastrointestinal tract, respiratory tract, skin, and bones and joints. Tolerability of these agents in usual doses has been good. Acquired bacterial resistance resulting from clinical uses has occurred in particular among staphylococci and Pseudomonas aeruginosa. Intense drug use and ability of resistant pathogens to spread have also contributed to development of resistance in initially more susceptible pathogens such as Escherichia coli and Neisseria gonorrhoeae in certain settings. Preservation of the considerable clinical utility of the quinolone class for the long term will be affected by the extent to which their use is judicious. 0167-4781/98/$ - see front matter (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:45 / 61
页数:17
相关论文
共 187 条
[1]  
Abeyewickereme I, 1996, GENITOURIN MED, V72, P302
[2]   HIGH-LEVEL QUINOLONE RESISTANCE AMONGST CLINICAL ISOLATES OF ESCHERICHIA-COLI AND KLEBSIELLA-PNEUMONIAE FROM SPAIN [J].
ALARCON, T ;
PITA, J ;
LOPEZBREA, M ;
PIDDOCK, LJV .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 32 (04) :605-609
[3]   USE OF QUINOLONES IN TREATMENT OF PROSTATITIS AND LOWER URINARY-TRACT INFECTIONS [J].
ANDRIOLE, VT .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1991, 10 (04) :342-350
[4]   ANTIMYCOPLASMAL ACTIVITIES OF NEW QUINOLONES, TETRACYCLINES, AND MACROLIDES AGAINST MYCOPLASMA-PNEUMONIAE [J].
ARAI, S ;
GOHARA, Y ;
KUWANO, K ;
KAWASHIMA, T .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (06) :1322-1324
[5]   REPRESSOR MUTATIONS IN THE MARRAB OPERON THAT ACTIVATE OXIDATIVE STRESS GENES AND MULTIPLE ANTIBIOTIC-RESISTANCE IN ESCHERICHIA-COLI [J].
ARIZA, RR ;
COHEN, SP ;
BACHHAWAT, N ;
LEVY, SB ;
DEMPLE, B .
JOURNAL OF BACTERIOLOGY, 1994, 176 (01) :143-148
[6]   Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients [J].
Arredondo, JL ;
Diaz, V ;
Gaitan, H ;
Maradiegue, E ;
Oyarzun, E ;
Paz, R ;
Reynal, JL ;
Stamm, W ;
Zambrano, D .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (02) :170-178
[7]   SINGLE-DOSE ENOXACIN COMPARED WITH 3-DAY TREATMENT FOR URINARY-TRACT INFECTION [J].
BACKHOUSE, CI ;
MATTHEWS, JA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (06) :877-880
[8]   NEISSERIA-GONORRHOEAE ACQUIRES MUTATIONS IN ANALOGOUS REGIONS OF GYRA AND PARC IN FLUOROQUINOLONE-RESISTANT ISOLATES [J].
BELLAND, RJ ;
MORRISON, SG ;
ISON, C ;
HUANG, WM .
MOLECULAR MICROBIOLOGY, 1994, 14 (02) :371-380
[9]   THERAPY FOR SHIGELLOSIS .2. RANDOMIZED, DOUBLE-BLIND COMPARISON OF CIPROFLOXACIN AND AMPICILLIN [J].
BENNISH, ML ;
SALAM, MA ;
HAIDER, R ;
BARZA, M .
JOURNAL OF INFECTIOUS DISEASES, 1990, 162 (03) :711-716
[10]   TREATMENT OF SHIGELLOSIS .3. COMPARISON OF ONE-DOSE OR 2-DOSE CIPROFLOXACIN WITH STANDARD 5-DAY THERAPY - A RANDOMIZED, BLINDED TRIAL [J].
BENNISH, ML ;
SALAM, MA ;
KHAN, WA ;
KHAN, AM .
ANNALS OF INTERNAL MEDICINE, 1992, 117 (09) :727-734